The people that president-elect Donald Trump has selected to lead federal health agencies in his second administration include a retired congressman, a surgeon and a former talk-show host. All of them could play pivotal roles in fulfilling a new political agenda that could change how the government goes about safeguarding Americans' health — from health care and medicines to food safety and science research. And if Congress approves, at the helm of the team as Department of Health and Human Services secretary will be prominent environmental lawyer and anti-vaccine organizer Robert F. Kennedy Jr. By and large, the nominees don't have experience running large bureaucratic agencies, but they know how to talk about health on TV . Centers for Medicare and Medicaid pick Dr. Mehmet Oz hosted a talk show for 13 years and is a well-known wellness and lifestyle influencer. The pick for the Food and Drug Administration, Dr. Marty Makary, and for surgeon general, Dr. Janette Nesheiwat, are frequent Fox News contributors. Many on the list were critical of COVID-19 measures like masking and booster vaccinations for young people. Some of them have ties to Florida like many of Trump's other Cabinet nominees: CDC pick Dr. Dave Weldon represented the state in Congress for 14 years and is affiliated with a medical group on the state's Atlantic coast. Nesheiwat's brother-in-law is Rep. Mike Waltz , R-Fla., tapped by Trump as national security adviser. Here's a look at the nominees' potential role in carrying out what Kennedy says is the task to “reorganize” agencies, which have an overall $1.7 billion budget; employ 80,000 scientists, researchers, doctors and other officials; and affect the lives of all Americans. Centers for Disease Control and Prevention The Atlanta-based CDC, with a $9.2 billion core budget, is charged with protecting Americans from disease outbreaks and other public health threats. Kennedy has long attacked vaccines and criticized the CDC, repeatedly alleging corruption at the agency. He said on a 2023 podcast that there is "no vaccine that is safe and effective,” and urged people to resist the CDC's guidelines on if and when kids should get vaccinated . Decades ago, Kennedy found common ground with Weldon , the 71-year-old nominee to run the CDC who served in the Army and worked as an internal medicine doctor before he represented a central Florida congressional district from 1995 to 2009. Starting in the early 2000s, Weldon had a prominent part in a debate about whether there was a relationship between a vaccine preservative called thimerosal and autism. He was a founding member of the Congressional Autism Caucus and tried to ban thimerosal from all vaccines. Kennedy, then a senior attorney for the Natural Resources Defense Council, believed there was a tie between thimerosal and autism and also charged that the government hid documents showing the danger. Since 2001, all vaccines manufactured for the U.S. market and routinely recommended for children 6 years or younger have contained no thimerosal or only trace amounts, with the exception of inactivated influenza vaccine. Meanwhile, study after study after study found no evidence that thimerosal caused autism. Weldon's congressional voting record suggests he may go along with Republican efforts to downsize the CDC, including to eliminate the National Center for Injury Prevention and Control, which works on topics like drownings, drug overdoses and shooting deaths. Weldon also voted to ban federal funding for needle-exchange programs as an approach to reduce overdoses, and the National Rifle Association gave him an “A” rating for his pro-gun rights voting record. Food and Drug Administration Kennedy is extremely critical of the FDA, which has 18,000 employees and is responsible for the safety and effectiveness of prescription drugs, vaccines and other medical products — as well as overseeing cosmetics, electronic cigarettes and most foods. Makary, Trump’s pick to run the FDA, is closely aligned with Kennedy on several topics . The professor at Johns Hopkins University who is a trained surgeon and cancer specialist has decried the overprescribing of drugs, the use of pesticides on foods and the undue influence of pharmaceutical and insurance companies over doctors and government regulators. Kennedy has suggested he'll clear our “entire” FDA departments and also recently threatened to fire FDA employees for “aggressive suppression” of a host of unsubstantiated products and therapies, including stem cells, raw milk , psychedelics and discredited COVID-era treatments like ivermectin and hydroxychloroquine. Makary's contrarian views during the COVID-19 pandemic including the need for masking and giving young kids COVID vaccine boosters. But anything Makary and Kennedy might want to do when it comes to unwinding FDA regulations or revoking long-standing vaccine and drug approvals would be challenging. The agency has lengthy requirements for removing medicines from the market, which are based on federal laws passed by Congress. Centers for Medicaid and Medicare Services The agency provides health care coverage for more than 160 million people through Medicaid, Medicare and the Affordable Care Act, and also sets Medicare payment rates for hospitals, doctors and other providers. With a $1.1 trillion budget and more than 6,000 employees, Oz has a massive agency to run if confirmed — and an agency that Kennedy hasn't talked about much when it comes to his plans. While Trump tried to scrap the Affordable Care Act in his first term, Kennedy has not taken aim at it yet. But he has been critical of Medicaid and Medicare for covering expensive weight-loss drugs — though they're not widely covered by either . Trump said during his campaign that he would protect Medicare, which provides insurance for older Americans. Oz has endorsed expanding Medicare Advantage — a privately run version of Medicare that is popular but also a source of widespread fraud — in an AARP questionnaire during his failed 2022 bid for a U.S. Senate seat in Pennsylvania and in a 2020 Forbes op-ed with a former Kaiser Permanente CEO. Oz also said in a Washington Examiner op-ed with three co-writers that aging healthier and living longer could help fix the U.S. budget deficit because people would work longer and add more to the gross domestic product. Neither Trump nor Kennedy have said much about Medicaid, the insurance program for low-income Americans. Trump's first administration reshaped the program by allowing states to introduce work requirements for recipients. Surgeon general Kennedy doesn't appear to have said much publicly about what he'd like to see from surgeon general position, which is the nation's top doctor and oversees 6,000 U.S. Public Health Service Corps members. The surgeon general has little administrative power, but can be an influential government spokesperson on what counts as a public health danger and what to do about it — suggesting things like warning labels for products and issuing advisories. The current surgeon general, Vivek Murthy, declared gun violence as a public health crisis in June. Trump's pick, Nesheiwat, is employed as a New York City medical director with CityMD, a group of urgent care facilities in the New York and New Jersey area, and has been at City MD for 12 years. She also has appeared on Fox News and other TV shows, authored a book on the “transformative power of prayer” in her medical career and endorses a brand of vitamin supplements. She encouraged COVID-19 vaccines during the pandemic, calling them “a gift from God” in a February 2021 Fox News op-ed, as well as anti-viral pills like Paxlovid. In a 2019 Q&A with the Women in Medicine Legacy Foundation , Nesheiwat said she is a “firm believer in preventive medicine” and “can give a dissertation on hand-washing alone.” National Institutes of Health As of Saturday, Trump had not yet named his choice to lead the National Institutes of Health, which funds medical research through grants to researchers across the nation and conducts its own research. It has a $48 billion budget. Kennedy has said he'd pause drug development and infectious disease research to shift the focus to chronic diseases. He'd like to keep NIH funding from researchers with conflicts of interest, and criticized the agency in 2017 for what he said was not doing enough research into the role of vaccines in autism — an idea that has long been debunked . ___ Associated Press writers Amanda Seitz and Matt Perrone and AP editor Erica Hunzinger contributed to this report. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.WASHINGTON , Dec. 5, 2024 /PRNewswire/ -- Shield AI, the defense technology company building autonomy for the world, has announced it is expanding its work with Palantir Technologies Inc. (NASDAQ: PLTR), a leading provider of AI systems, to develop and deliver large-scale command and control of autonomous uncrewed systems, including operations in GPS- and communications-denied environments. With Warp Speed, Palantir's manufacturing OS for American re-industrialization, Shield AI is doubling down on its commitment to delivering scalable, AI-powered solutions to protect service members and civilians. By leveraging Shield AI's advanced Hivemind software development kit, along with Palantir's suite of powerful software solutions—including enterprise resource planning, geospatial intelligence, and operational decision-making tools—the partnership combines the strengths of both companies to address the most critical defense challenges. "Shield AI and Palantir have both built technology products proven in the most demanding environments," said Brandon Tseng , Shield AI's President, Co-founder, and former Navy SEAL. "Our partnership is about bringing together Palantir's software dominance and Shield AI's expertise in autonomy to deliver the best possible outcomes for customers. It's exciting to scale up what we've been working on together in this next chapter of our partnership." This announcement builds on work Shield AI and Palantir showcased at the Association of the U.S. Army's (AUSA) Annual Meeting and Expo in October, where the companies demonstrated the integration of Shield AI's Hivemind with Palantir's Gaia. This integration created a unified command-and-control system for autonomous systems. Hivemind's proven autonomy capabilities—demonstrated on platforms like the V-BAT , F-16, MQM-178 Firejet, and Nova quadcopter—now seamlessly integrate with Gaia's geospatial intelligence tools, enabling real-time mission execution and precision targeting. "The American Industrial Base needs Warp Speed," said Shyam Sankar , Palantir's Chief Technology Officer and Executive Vice President. "Shield AI stands out in their field, having achieved mission impact and product results where others have struggled. This partnership, and Shield AI's deploying of our newly announced manufacturing OS will enable faster and better delivery to customers, and ultimately aid in the defense of the West." About Palantir Technologies Inc. Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir's expectations regarding the amount and the terms of the contract and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms' reliability; and our customer's ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise. Media Contact Lisa Gordon, media@palantir.com About Shield AI Founded in 2015, Shield AI is a venture-backed defense technology company whose mission is to protect service members and civilians with intelligent systems. In pursuit of this mission, Shield AI is building the world's best AI pilot. Its AI pilot, Hivemind, has flown jets (F-16; MQM-178 Firejet), a vertical takeoff and landing drone (MQ-35 V-BAT), and three quadcopters (Nova, Nova 2, iPRD). The company has offices in San Diego , Dallas , Washington DC and abroad. Shield AI's products and people are currently in the field actively supporting operations with the U.S. Department of Defense and U.S. allies. For more information, visit www.shield.ai. Follow Shield AI on LinkedIn, X and Instagram. Media Contact Lily Hinz , media@shield.ai View original content to download multimedia: https://www.prnewswire.com/news-releases/shield-ai-and-palantir-technologies-deepen-strategic-partnership-and-announce-deployment-of-warp-speed-302324396.html SOURCE Shield AI
Not-So-New News Flash? Change in Administration Ushers Back a Deregulatory Agenda – Implications for Investment Advisers
Andy Murray enters new chapter with Novak Djokovic as coach of long-time rivalDePaul cruises to win over Loyola MarylandNEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ: 226330), a leading artificial intelligence (AI)-driven drug development company, is pleased to announce its participation in Biotech Showcase 2025, taking place January 13-15, 2025, in San Francisco. As a leader in advanced AI drug discovery, Syntekabio is committed to helping its partners accelerate timelines, reduce costs, and improve outcomes in the development of novel therapies. Attendees will have the opportunity to learn more about the Company's innovative solutions and its 'Develop Now, Pay Later' offer, which enables pharmaceutical and biotechnology companies to test the validity of a target protein of interest without incurring any upfront costs. Should a project demonstrate viability, Syntekabio then employs its STB LaunchPad program, powered by its proprietary AI-driven DeepMatcher ® technology platform, to deliver hits and optimized leads as well as IND-enabled candidates. Jongsun Jung, PhD, CEO of Syntekabio, emphasized the company's focus on innovation: "Biotech Showcase is a great opportunity for us to connect with industry leaders and discuss how our AI-powered solutions can drive transformative change in drug discovery. At Syntekabio, we are committed to delivering solutions that help our partners advance innovative treatments faster, ultimately benefiting patients worldwide." To schedule a meeting with Syntekabio in San Francisco and learn how our innovative AI solutions can support your R&D efforts, please use the Biotech Showcase partnering system or reach out here . About Syntekabio Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The Company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio's disease-agnostic physics-based platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The Company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications. Visit the Syntekabio website at www.syntekabio.com or follow the Company on LinkedIn for the latest updates. Contact Syntekabio USA, Inc Joonhyuk Choi, CEO +1 212-371-2544 [email protected] Media Contact: MC Services AG Europe: Dr. Cora Kaiser +49 89 210 228 0 US: Laurie Doyle +1 339 832 0752 [email protected]
An Idaho teenager has been arrested in connection with the body of an infant found last month at a hospital in a box meant for people to anonymously give up a newborn, police said Friday. The Blackfoot Police Department said in a social media post that an 18-year-old from Twin Falls, about 130 miles (210 kilometers) southeast of Boise, had been arrested there and booked into the Bingham County Jail. She was arrested on a felony arrest warrant for failing to report a death to law enforcement officials and the coroner, police said. Police in Blackfoot responded to a report Oct. 13 of a deceased baby left at Grove Creek Medical Center. Safe Haven Baby Boxes founder Monica Kelsey has said hospital staff responded immediately to an alarm indicating a baby was in the box and realized that the infant had died before being placed inside. Idaho law only allows for the surrender of an infant who is unharmed. “The Safe Haven Baby Box is intended to safely and anonymously allow custodial parents to surrender a newborn under 30 days old without legal repercussions, provided the child is unharmed," police said in the social media post. "Unfortunately, the placement of a harmed or deceased infant is not protected under this system or Idaho law." The baby had been wrapped in a blanket, and the placenta was still attached, Kelsey said previously. Police said they weren't releasing further information in part because more charges could be filed.
Stock market today: Wall Street edges back from its records as bitcoin briefly pops above $100,000
Tarabot Foundation's CEO Dr. Fatima Al Bakheet and Nuzol Al Ansari Project Recognized at HBC 2024 International AwardsCDS: National Security Embodies Social, Economic, Environmental Elements
